文献速递肝病消化道肿瘤与早癌

整合表观遗传学分析揭示肝细胞癌中DNA甲基转移酶抑制剂Guadecitabine(SGI-110)的治疗靶点

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2018-01-01

研究利用三种肝细胞癌细胞系(SNU398、HepG2、SNU475)进行短暂SGI-110处理,整合分析DNA甲基化、核小体可及性、基因表达谱,并与TCGA肝细胞癌临床数据比较。结果显示SGI-110可上调肿瘤抑制基因、下调癌基因、双重抑制PRC2并激活内源性逆转录病毒及免疫通路,约48%的肝细胞癌常见突变基因可被逆转。

要点

  • SGI-110处理使三种肝细胞癌细胞系均敏感并产生持久抗增殖效应。
  • 上调基因表达与核小体可及性正相关、与启动子DNA甲基化负相关。
  • SGI-110可下调PRC2基因并激活内源性逆转录病毒及免疫通路。

核心结论

  • 整合分析将SGI-110的抗肿瘤效应与肝细胞癌细胞的详细表观遗传改变相关联,识别了潜在治疗靶点,并为SGI-110联合免疫检查点治疗提供了依据。

研究设计与样本

  • 研究使用肝细胞癌细胞系SNU398、HepG2和SNU475,基于TCGA数据各代表原发肝细胞癌的一种DNA甲基化亚型,评估短暂SGI-110处理后的DNA甲基化、核小体可及性、基因表达谱,并与TCGA肝细胞癌临床数据比较。

主要发现

  • SGI-110处理后所有细胞系均敏感,并具有持久抗增殖效应。
  • 上调基因(包括肿瘤抑制基因)的表达与核小体可及性正相关、与基因启动子DNA甲基化负相关。
  • 下调基因(如癌基因)的表达与核小体可及性负相关、与基因体DNA甲基化正相关。
  • SGI-110通过去甲基化PRC2基因体下调PRC2,重新激活PRC2抑制基因而不涉及DNA甲基化。
  • SGI-110可上调内源性逆转录病毒以重新激活免疫通路,约48%的原发肝细胞癌常见突变基因可被SGI-110逆转。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: There is an urgent need to develop more effective therapies for hepatocellular carcinoma (HCC) because of its aggressiveness. Guadecitabine (SGI-110) is a second-generation DNA methyltransferase inhibitor (DNMTi), which is currently in clinical trials for HCC and shows greater stability and performance over first-generation DNMTis. In order to identify potential therapeutic targets of SGI-110 for clinical trials, HCC cell lines (SNU398, HepG2, and SNU475) were used to evaluate the effects of transient SGI-110 treatment by an integrative analysis of DNA methylation, nucleosome accessibility, gene expression profiles, and its clinical relevance by comparison to The Cancer Genome Atlas (TCGA) HCC clinical data. Each HCC cell line represents a different DNA methylation subtype of primary HCC tumors based on TCGA data. After SGI-110 treatment, all cell lines were sensitive to SGI-110 with prolonged antiproliferation effects. Expression of up-regulated genes, including tumor suppressors, was positively correlated with nucleosome accessibility and negatively correlated with gene promoter DNA methylation. Alternatively, expression of down-regulated genes, such as oncogenes, was negatively correlated with nucleosome accessibility and positively correlated with gene body DNA methylation. SGI-110 can also act as a dual inhibitor to down-regulate polycomb repressive complex 2 (PRC2) genes by demethylating their gene bodies, resulting in reactivation of PRC2 repressed genes without involvement of DNA methylation. Furthermore, it can up-regulate endogenous retroviruses to reactivate immune pathways. Finally, about 48% of frequently altered genes in primary HCC tumors can be reversed by SGI-110 treatment. CONCLUSION: Our integrative analysis has successfully linked the antitumor effects of SGI-110 to detailed epigenetic alterations in HCC cells, identified potential therapeutic targets, and provided a rationale for combination treatments of SGI-110 with immune checkpoint therapies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Liu M, Zhang L, Li H, et al. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology. 2018. PMID: 29774579. doi:10.1002/hep.30091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。